Hwang Angela
Known title: Group PresidentCIK: 0001725474
Associated companies
Transaction History
| PFE | ▲ Buy | Option Exercise | 20,273 | $464K | 2/25/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 5,748 | $240K | 2/25/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 9,015 | $392K | 2/25/2023 | View on chart |
| PFE | ▲ Buy | Option Exercise | 57,032 | $1.7M | 2/22/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 8,041 | $341K | 2/22/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 34,718 | $1.5M | 2/22/2023 | View on chart |
| PFE | ▲ Buy | Option Exercise | 12,716 | $326K | 2/26/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 3,461 | $165K | 2/26/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 5,937 | $301K | 2/26/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 21,359 | $584K | 2/23/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 4,110 | $193K | 2/23/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 10,572 | $542K | 2/23/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 800 | $40K | 11/12/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 3,412 | $169K | 11/12/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 10,646 | $528K | 11/12/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 11,312 | $561K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff
Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.